Why Regeneron's Results for Its COVID Antibody Therapy Won't Boost Sales Much

Regeneron Pharmaceuticals (NASDAQ: REGN) and its partner, Roche (OTC: RHHBY), recently reported positive results from a late-stage study of COVID-19 antibody therapy REGEN-COV as a prophylaxis. In this Motley Fool Live video recorded on Nov. 10, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why these results probably won't lead to significantly higher sales for the therapy.

Continue reading

Source Fool.com